| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 12,286,646 | 15,247,910 | ||
| Restricted cash | 100,000 | 100,000 | ||
| Prepaid expenses and other current assets | 633,533 | 199,615 | ||
| Total current assets | 13,020,179 | 15,547,525 | ||
| Equipment, net | 1,360 | 2,721 | ||
| Goodwill | 14,869,399 | 14,869,399 | ||
| Deferred offering costs | 201,114 | - | ||
| Total assets | 28,092,052 | 30,419,645 | ||
| Accounts payable | 944,492 | 896,799 | ||
| Accrued expenses and other current liabilities | 1,727,830 | 1,632,059 | ||
| Total current liabilities | 2,672,322 | 2,528,858 | ||
| Liability related to the sale of future royalties | 60,000,000 | 60,000,000 | ||
| Total liabilities | 62,672,322 | 62,528,858 | ||
| Common stock 0.0001 par value 125,000,000 shares authorized 6,993,406 shares issued and outstanding as of september 30, 2025 and december 31, 2024 | 699 | 699 | ||
| Additional paid-in capital | 370,551,108 | 370,278,211 | ||
| Accumulated deficit | -405,132,077 | -402,388,123 | ||
| Total stockholders' deficit | -34,580,270 | -32,109,213 | ||
| Total liabilities and stockholders' deficit | 28,092,052 | 30,419,645 | ||
Minerva Neurosciences, Inc. (NERV)
Minerva Neurosciences, Inc. (NERV)